Received: 12 February 2018
Accepted: 9 July 2018
First Online: 1 August 2018
Ethics approval and consent to participate
: Ethics approval from the Massachusetts General Hospital Institutional Review Board (ref: 15–354), and Vanderbilt University Institutional Review Board (ref: 150370) was sought and obtained for site-specific patient recruitment.An approval from an Independent Review Board (New England IRB, ref.: 16–187) was also obtained to allow recruitment for additional patients.Clinician confirmation of diagnosis and treatment were obtained for all patients. An informed consent process was undertaken with all patients, all data were anonymised and held confidentially.
: Patient quotes are reported anonymously. Informed consent forms stated that patients would not be identified if information about this study is published, and patients were informed that their comments would be reported anonymously prior to the interview.
: A Degboe and K Halling are employees of AstraZeneca LP. SL Knight, H Kitchen, N Aldhouse and T Al-Zubeidi are employees of DRG Abacus, A Trigg was an employee of DRG Abacus at the time of manuscript development. DRG Abacus is a health outcomes agency that consults with various pharmaceutical companies. AstraZeneca LP have commissioned DRG Abacus to consult on health economic strategies for their forthcoming studies.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.